Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UCB Predicts Briviact Sales Of €450m by 2026; Plans New Partnerships

Executive Summary

UCB says its early to mid-stage pipeline contains 10 promising breakthrough molecules, some of which it aims to partner with other pharma players as part of its open innovation strategy.

You may also be interested in...

Zydus Sets Sight On First US Generic Of UCB’s Briviact

Zydus Cadila has scooped another material ANDA approval from the FDA, with the green light for its generic version of UCB’s Briviact to treat partial-onset seizures.

UCB’s Cimzia Set To Make A Late Entrance At Psoriasis Party

UCB has reported positive data from the final Phase III trial of its anti-TNF product Cimzia in plaque psoriasis, paving the way for approval applications later this year, but the product will have to elbow its way into a competitive market already under the shadow of a biosimilar threat.

UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures

A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts